These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34882875)

  • 1. Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
    Sebai M; Tulasne D; Caputo SM; Verkarre V; Fernandes M; Guérin C; Reinhart F; Adams S; Maugard C; Caron O; Guillaud-Bataille M; Berthet P; Bignon YJ; Bressac-de Paillerets B; Burnichon N; Chiesa J; Giraud S; Lejeune S; Limacher JM; de Pauw A; Stoppa-Lyonnet D; Zattara-Cannoni H; Deveaux S; Lidereau R; Richard S; Rouleau E
    Hum Mutat; 2022 Mar; 43(3):316-327. PubMed ID: 34882875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary papillary renal cell carcinoma.
    Jacoba IM; Lu Z
    Semin Diagn Pathol; 2024 Jan; 41(1):28-31. PubMed ID: 38135585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
    Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
    Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene.
    Schmidt LS; Nickerson ML; Angeloni D; Glenn GM; Walther MM; Albert PS; Warren MB; Choyke PL; Torres-Cabala CA; Merino MJ; Brunet J; Bérez V; Borràs J; Sesia G; Middelton L; Phillips JL; Stolle C; Zbar B; Pautler SE; Linehan WM
    J Urol; 2004 Oct; 172(4 Pt 1):1256-61. PubMed ID: 15371818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma.
    Wadt KA; Gerdes AM; Hansen TV; Toft BG; Friis-Hansen L; Andersen MK
    Fam Cancer; 2012 Sep; 11(3):535-7. PubMed ID: 22717761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
    Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
    Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
    Schmidt L; Duh FM; Chen F; Kishida T; Glenn G; Choyke P; Scherer SW; Zhuang Z; Lubensky I; Dean M; Allikmets R; Chidambaram A; Bergerheim UR; Feltis JT; Casadevall C; Zamarron A; Bernues M; Richard S; Lips CJ; Walther MM; Tsui LC; Geil L; Orcutt ML; Stackhouse T; Lipan J; Slife L; Brauch H; Decker J; Niehans G; Hughson MD; Moch H; Storkel S; Lerman MI; Linehan WM; Zbar B
    Nat Genet; 1997 May; 16(1):68-73. PubMed ID: 9140397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
    Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
    Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.
    Lubensky IA; Schmidt L; Zhuang Z; Weirich G; Pack S; Zambrano N; Walther MM; Choyke P; Linehan WM; Zbar B
    Am J Pathol; 1999 Aug; 155(2):517-26. PubMed ID: 10433944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
    Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
    Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report.
    Ferlicot S; Just PA; Compérat E; Rouleau E; Tissier F; Vaessen C; Richard S
    Diagn Pathol; 2021 Nov; 16(1):107. PubMed ID: 34801057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
    Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
    Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.
    Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM
    Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.
    Olivero M; Valente G; Bardelli A; Longati P; Ferrero N; Cracco C; Terrone C; Rocca-Rossetti S; Comoglio PM; Di Renzo MF
    Int J Cancer; 1999 Aug; 82(5):640-3. PubMed ID: 10417759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary papillary renal carcinoma type I.
    Dharmawardana PG; Giubellino A; Bottaro DP
    Curr Mol Med; 2004 Dec; 4(8):855-68. PubMed ID: 15579033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphasic papillary (biphasic squamoid alveolar) renal cell carcinoma: a clinicopathologic and molecular study of 17 renal cell carcinomas including 10 papillary adenomas.
    Nova-Camacho LM; Acosta AM; Akgul M; Panizo A; Galea LA; Val-Carreres A; Talavera JA; Guerrero-Setas D; Martin-Arruti M; Ruiz I; García-Martos M; Sangoi AR
    Virchows Arch; 2024 Mar; 484(3):441-449. PubMed ID: 38388964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways.
    Wala SJ; Karamchandani JR; Saleeb R; Evans A; Ding Q; Ibrahim R; Jewett M; Pasic M; Finelli A; Pace K; Lianidou E; Yousef GM
    Mol Oncol; 2015 Oct; 9(8):1667-77. PubMed ID: 26051997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours.
    Fischer J; Palmedo G; von Knobloch R; Bugert P; Prayer-Galetti T; Pagano F; Kovacs G
    Oncogene; 1998 Aug; 17(6):733-9. PubMed ID: 9715275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
    Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
    Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
    Schmidt L; Junker K; Weirich G; Glenn G; Choyke P; Lubensky I; Zhuang Z; Jeffers M; Vande Woude G; Neumann H; Walther M; Linehan WM; Zbar B
    Cancer Res; 1998 Apr; 58(8):1719-22. PubMed ID: 9563489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.